Mavenir Wins Best 5G Core and Best OpenRAN at 5G World 2020
Mavenir, the industry’s only end-to-end cloud-native 4G/5G Network Software Provider focused on accelerating digital transformation for Communications Service Providers (CSPs), was recognized for its continuous network and service innovation, taking home two awards for “Best 5G Core” and “Best OpenRAN” at the 5G World Awards 2020, hosted by Informa Tech.
Leveraging Mavenir’s technology innovation DNA, both the OpenRAN vRAN and 5G Core use cloud-native architecture and open interfaces, following web-scale principles to provide the required scalability, agility and reliability in order to support the wide range of 5G use cases and meet stringent 5G performance requirements. In addition, both are fully containerized solutions and share a common integration and management layer.
“Mavenir continues to drive forward with advanced cloud-native solutions that are recognized by our customers and the industry. Our Cloud Packet Core and OpenRAN vRAN solutions embrace disruptive technology architectures and business models that drive network agility, deployment flexibility, and service velocity,” said Pardeep Kohli, President and CEO of Mavenir. “With our cloud-native, end-to-end software portfolio and our extensive experience/knowledge with all the key network components, we are uniquely positioned to enable mobile operators to transform and future proof their networks.”
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. www.mavenir.com
Mavenir, the M logo, and Cloud Range are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005696/en/
Contact information
Maryvonne Tubb
Mavenir PR
NA-Loren Guertin
MatterNow
EMEA-Kevin Taylor
GlobalResultsPR
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor2.12.2020 00:00:00 CET | Press release
LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TT-01025, a novel SSAO/VAP-1 inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) and other inflammatory diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201006171/en/ LG Chem will initiate the Phase 1 clinical trial at PPDLas Vegas Clinical Research Unit in Las Vegas, NV, United States to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TT-01025 in healthy subjects. The trial is expected to be initiated in the first quarter of 2021. “As liver manifestation of a metabolic disorder, NASH is a potentially life threatening condition which increases cardiovascular risk and can lead to
Anark Deepens Commitment to Customer Engagement with Additions to Executive Leadership Team, Marketing, and Sales Enablement1.12.2020 20:51:00 CET | Press release
Anark Corporation, a leading provider of Intelligent Information Management (IIM) and collaboration software, announced today that Greg Caldwell, former marketing executive at 3D Systems and Microsoft, has joined as Vice President of Marketing and Sales Enablement. Caldwell will join the executive leadership team and be responsible for elevating Anark’s global brand, expanding market opportunity, and growing the business. Caldwell is a seasoned marketer, strategist, and business leader with an extensive background in IT hardware, software, and manufacturing. Throughout his career he has always believed in putting the customer first and creating modern, relevant, digital initiatives that help customers educate themselves and make more informed buying decisions. Prior to joining Anark in November of 2020, Caldwell was Vice President of Marketing and Communications at 3D Systems, one of the world’s leading additive manufacturing companies. Before 3D Systems, he spent almost 11 years as Gl
Lineage Logistics Enters the Polish Cold Storage Market With the Acquisition of Pago Sp. z o.o.1.12.2020 18:04:00 CET | Press release
Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced it has acquired Pago Sp. z o.o. (“Pago”), a leading warehousing, distribution and transport logistics provider in Poland from its current ownership, including Tönnies International Holding GmbH (“Tönnies”). The strategic acquisition marks the Company’s entrance into the Polish market and adds six exceptional assets to Lineage’s global network of temperature-controlled facilities. Lineage was founded and continues to be managed by Bay Grove Capital, LLC (“Bay Grove”), a principal investment firm dedicated to partnering with strong management teams to build long-term platform investments. Financial terms of the transactions were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005951/en/ The acquisition of Pago Sp. z o.o
Sumitomo SHI FW fluidized bed technology – upscaling thermochemical energy storage to a commercial level1.12.2020 17:47:00 CET | Press release
One of the largest obstacles in using renewable energy efficiently is the possibility to store energy on a large scale. SaltX Technology AB has partnered with Sumitomo SHI FW (SFW) to solve this in terms of heat energy. "The storage solution is like a "salt battery". It is based on a basic chemical process with a very common material, calcium oxide produced from limestone, with enhanced properties by our nanocoating process", explains Carl-Johan Linér, CEO of SaltX. Simplified, when calcium oxide reacts with water, it turns into calcium hydroxide and releases heat. Respectively, when calcium hydroxide is dried, it absorbs heat. SFW has designed a fluidized bed pilot reactor, which serves as the point of discharge, where the salt releases the heat. The new 100 kW reactor in SaltX's new testing installation in Sweden, near Stockholm, combines the performance of SaltX's patented nanocoated salt with SFW's fluidized bed technology. "SFW's technology has huge potential to take the salt batt
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets1.12.2020 17:00:00 CET | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina® Focus Panel, AmpliSeq™ for Illumina® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio. Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic report
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 16:01:00 CET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity